Adcendo ApS to Present Data on its Novel ADC Target uPARAP in Glioblastoma Multiforme at the American Association for Cancer Research Annual Meeting 2024
- Data demonstrate that uPARAP is highly expressed in tumor samples obtained from glioblastoma multiforme patients
- uPARAP targeting ADC shows cytotoxicity in glioblastoma multiforme cancer cells in vitro and exhibits potent in vivo anti-tumor activity in a glioblastoma multiforme PDX model
- Data provides evidence that uPARAP targeting ADCs are a potential novel treatment option for glioblastoma multiforme patients
Copenhagen, Denmark, April 4th, 2024 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of first-in-class antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, will be presenting novel data on the expression of its novel ADC target uPARAP and the in vitro and in vivo activity of a uPARAP targeting ADC in glioblastoma multiforme (GBM) at the American Association for Cancer Research (AACR) Annual Meeting, held in San Diego, California, from April 5th to April 10th, 2024. The data has been evaluated in collaboration with the Finsen Laboratory, Rigshospitalet/BRIC, University of Copenhagen, Copenhagen, Denmark.
